☆ 4.4 Article

Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

CLINICAL LUNG CANCER (2021)

Get Full Text
Add to Collection

Journal

CLINICAL LUNG CANCER
Volume 22, Issue 4, Pages E528-E532

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2020.04.012

Keywords

Alectinib hepatotoxicity; ALK; CNS efficacy of brigatinib; CNS relapse; Dose-escalated brigatinib

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.